<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806451</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-74788-CAH2006</org_study_id>
    <secondary_id>2020-004381-19</secondary_id>
    <nct_id>NCT04806451</nct_id>
  </id_info>
  <brief_title>Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont&#xD;
      versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic&#xD;
      congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of&#xD;
      a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with&#xD;
      crinecerfont. Duration of participation is approximately 14 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Serum Androstenedione (A4) at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Serum 17-hydroxyprogesterone (17-OHP) at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Glucocorticoid Daily Dose at Week 28</measure>
    <time_frame>Baseline to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of a reduction in glucocorticoid daily dose to physiologic levels at Week 28</measure>
    <time_frame>Baseline to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body mass index at Week 28</measure>
    <time_frame>Baseline to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in salivary 17-OHP at Week 28</measure>
    <time_frame>Baseline to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone age advancement at Week 28</measure>
    <time_frame>Baseline to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in predicted adult height at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Crinecerfont</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinecerfont</intervention_name>
    <description>CRF1-receptor antagonist</description>
    <arm_group_label>Crinecerfont</arm_group_label>
    <other_name>NBI-74788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-active dosage form</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinecerfont</intervention_name>
    <description>CRF1-receptor antagonist</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NBI-74788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to adhere to the study procedures, including all requirements at&#xD;
             the study center, and return for the follow-up visit.&#xD;
&#xD;
          -  Have a medically confirmed diagnosis of 21-hydroxylase deficiency CAH.&#xD;
&#xD;
          -  Be on a stable regimen of steroidal treatment for CAH.&#xD;
&#xD;
          -  Have elevated androgen levels.&#xD;
&#xD;
          -  Patients of childbearing potential must be abstinent or agree to use appropriate birth&#xD;
             control during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of any of the other forms of classic CAH.&#xD;
&#xD;
          -  Have a history of bilateral adrenalectomy, hypopituitarism, or other condition&#xD;
             requiring chronic glucocorticoid therapy.&#xD;
&#xD;
          -  Have a clinically significant unstable medical condition or chronic disease other than&#xD;
             CAH.&#xD;
&#xD;
          -  Have a history of cancer unless considered to be cured.&#xD;
&#xD;
          -  Have a known history of clinically significant arrhythmia or abnormalities on ECG.&#xD;
&#xD;
          -  Have a known hypersensitivity to any corticotropin-releasing hormone antagonist.&#xD;
&#xD;
          -  Have received an investigational drug within 30 days before initial screening or plan&#xD;
             to use an investigational drug (other than the study drug) during the study.&#xD;
&#xD;
          -  Have current substance dependence or substance (drug) or alcohol abuse.&#xD;
&#xD;
          -  Have had a significant blood loss or donated blood or blood products within 8 weeks&#xD;
             prior to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neurocrine Medical Information Call Center</last_name>
    <phone>877-641-3461</phone>
    <email>medinfo@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cahtalystpeds.cahstudies.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>classic congenital adrenal hyperplasia (CAH)</keyword>
  <keyword>21-hydroxylase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

